Arbutus Biopharma ( (ABUS) ) has released its Q3 earnings. Here is a breakdown of the information Arbutus Biopharma presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in the development of treatments for infectious diseases, with a focus on chronic hepatitis B virus (cHBV) infection. The company has reported its third-quarter 2025 financial results, highlighting a strong cash position of $93.7 million and significant progress in its clinical trials for imdusiran (AB-729), a promising therapeutic candidate for cHBV.
In the recent quarter, Arbutus achieved notable milestones in its clinical trials, with 46% of Phase 2a patients meeting criteria to discontinue all treatment and 94% of long-term follow-up patients remaining off treatment for over two years. Additionally, 100% of HBV DNA positive patients in Phase 1b trials achieved undetectable HBV DNA levels after 18 weeks of treatment. These results underscore imdusiran’s potential as a groundbreaking therapy for cHBV.
Financially, Arbutus reported a net loss of $7.7 million for the quarter, a significant improvement from the $19.7 million loss in the same period last year. The company has implemented cost-cutting measures, reducing research and development expenses by $8.5 million and general administrative expenses by $1.5 million compared to the previous year. These efforts are part of a strategic focus on advancing imdusiran and AB-101, another promising candidate in their pipeline.
Arbutus is also actively engaged in litigation to protect its intellectual property related to lipid nanoparticle (LNP) technology, which is crucial for the success of COVID-19 vaccines by Moderna and Pfizer/BioNTech. Trials and hearings are scheduled for 2026 and beyond, as Arbutus seeks fair compensation for the use of its patented technology.
Looking ahead, Arbutus remains committed to accelerating the development of imdusiran, with a focus on achieving regulatory approval and expanding its clinical programs. The company is poised to continue its strategic initiatives while navigating ongoing litigation and maintaining financial discipline.